Posaconazole
Posaconazole (SCH 56592), an unapproved azole available from the manufacturer for compassionate use, isunder review by the FDA for oral treatment of invasive fungal infections, containing aspergillosis, fusariosis, and zygomycosis in patients who are intolerant of or refractory to other therapy. Posaconazole appears to have same activity to fluconazole and itraconazole against Candida spp. but is more active against Zygomycetes (Mucor spp. and Rhizomucor spp.). Currently, amphotericin B is the only drug available to treat Mucor.